Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947346 | 0.93 | NSD2 (0.48) | NSD2CTSLCTSBCTSSPOLB | |
| SCHEMBL1009189 | 0.87 | NSD2 (0.45) | NSD2CTSLCTSBCTSSPOLB | |
| SCHEMBL29637970 | 0.86 | NSD2 (0.45) | NSD2CTSLCTSBCTSSPOLB | |
| SCHEMBL21996676 | 0.86 | PPARA (0.43) | NSD2EPHX2TSHRCYP2A6PPARD | |
| SCHEMBL21997473 | 0.85 | CTSS (0.46) | NSD2CTSLCTSBCTSSHTR2C | |
| SCHEMBL30275188 | 0.85 | CTSL (0.41) | NSD2CTSLCTSBCTSSHTR2C | |
| SCHEMBL6424007 | 0.84 | NSD2 (0.43) | NSD2CTSLCTSBCTSSPOLB | |
| SCHEMBL21998217 | 0.83 | PPARA (0.41) | NSD2EPHX2TSHRPPARDPPARA | |
| SCHEMBL320434 | 0.83 | MEP1A (0.49) | CTSLCTSBCTSSCHRM2CHRM1 | |
| SCHEMBL1009190 | 0.83 | NSD2 (0.42) | NSD2CTSLCTSBCTSSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066896-A1 | G9A INHIBITOR | RIKEN (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2021034924-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| WO-2013132253-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2013-09-12 | — | — | WO | disclosed |
| US-6646124-B2 | Gamma-aminobutyric acid (GABA) agonists, antagonists or inverse agonists; treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs | NEUROGEN CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2002-10-24 | — | — | US | disclosed |
| US-6399604-B1 | ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, AND OVERDOSE WITH BENZODIAZEPINE DRUGS | NEUROGEN CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-6143760-A | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6114390-A | AN ARGININAMIDE OR ORNITHINAMIDE COMPOUND AS TREATING MEMORY LOSS, MIGRAINE, SLEEP DISORDERS, PAIN, CARDIOVASCULAR DISEASES, SUBARACHNOIDAL BLEEDING, VASCULAR-HYPERTROPHIC CHANGES, CEREBRAL AND CORONARY VASOSPASMS | KARL THOMAE GMBH (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-1007526-A1 | SUBSTITUTED 4-OXO-NAPTHYRIDINE-3-CARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010347-A1 | SUBSTITUTED 4-OXO-NAPTHYRIDINE-3-CARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0885186-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | GABRA4, GABRA1, GABRA2 | NSD2 983/4885CTSL 3809/4885CTSB 4215/4885 |
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | NSD2 57/4885CTSL 4707/4885CTSB 4560/4885 |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | TK1, TTR, TALDO1 | NSD2 4648/4885CTSL 2050/4885CTSB 1526/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | NSD2 1273/4885CTSL 2525/4885CTSB 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.